SCLX Stock — Scilex Holding Company

Scilex Holding Company (SCLX)

Updated October 16, 2026.

SCLX is a Stock. Total return is -98.7% over the past 5.6 years, 213.5 points behind SPY at 114.8%.

Scilex Holding Company is a biopharmaceutical company focused on developing and commercializing non-opioid pain management products, including marketed treatments such as ZTlido (a lidocaine topical system for nerve pain), ELYXYB (an oral solution for acute migraine), and GLOPERBA (an oral colchicine formulation for gout), alongside a pipeline of candidates in development for conditions including sciatica and fibromyalgia. The company does not currently have an established distribution schedule. Scilex appeals to investors seeking exposure to specialized pharmaceutical development in the pain management space, though as an early-to-mid stage commercial biotech company it carries typical clinical and commercial execution risks.

SCLX performance versus SPY

Price and return data through 2026-10-16.

Total return is -98.7% over the past 5.6 years, 213.5 points behind SPY at 114.8%. Over the past year its total return — price change plus distributions reinvested — is -65.8%. Its deepest 1-year drawdown was 80.0%.

SCLX key facts

Asset type

Stock

Asset class

Equity

Inception date

03/05/2021

Distribution frequency

None

Last close

$2.83 (as of 2026-10-16)

Market cap

$19,908,306

Average volume

29519.0

Beta

1.792

Payout ratio

0.0%

Forward P/E

5.5772

EPS

$-49.70

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

SCLX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 80.0%.

Who may consider SCLX — and who may not

It is a weaker fit for investors who need monthly cash flow (SCLX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on SCLX

• All tickers starting with S

Tagged: Healthcare.

Frequently asked questions